Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SAN DIEGO, Oct. 24, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced the appointment of Philippe Schaison to its Board of Directors effective immediately.
"We are thrilled to have Philippe join the SENTÉ team,” said Faheem Hasnain, Chairman of the Board of Directors of SENTÉ. “He brings a tremendous set of expertise and validation to our company during this exciting next phase of growth. Philippe is a high ranking industry veteran and will be a valuable asset in helping the company evolve into a major aesthetics contender.”
Mr. Schaison brings to SENTÉ over 20 years of experience in the skin care industry. Currently, he is Chief Executive Officer of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Most recently he served as President of Allergan US Aesthetic and Dermatology, where he led a $2 billion U.S. Aesthetic and Dermatology business since 2013, with responsibility for Allergan's top aesthetic brands, including Botox, Juvederm, Kybella and SkinMedica, and other leading brands. Prior to Allergan, Mr. Schaison served in leadership roles at several aesthetic businesses, including Clarins, Johnson & Johnson where he served as VP of Global Skin Care, and L’Oréal. Mr. Schaison received a Master of Business Administration in Marketing from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy from the University of Paris V.
"I am excited and honored to have the opportunity to play a key role in SENTÉ’s already robust and experienced Board of Directors,” said Philippe Schaison. “SENTÉ has assembled a world class team and a market disrupting technology that the aesthetics industry has been waiting for. I am looking forward to being a part of this compelling growth story and helping SENTÉ become a leading brand in the space.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycan’s. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
